Navigation Links
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
Date:6/26/2010

ORLANDO, Fla., June 26 /PRNewswire/ -- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2)  Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes. The linagliptin data are being presented this week at the 70th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando, Fla.

In the Phase III studies, statistically significant placebo-adjusted changes in HbA1c were observed with linagliptin (5 mg) monotherapy versus placebo (-0.69 percent, p<0.0001)(1) and when used in combination with other commonly-used oral anti-diabetic drugs, including metformin (-0.64 percent, p<0.0001),(2) metformin plus a sulfonylurea (-0.62 percent, p<0.0001),(3) and as initial combination with pioglitazone (-0.51 percent, p<0.0001).(4) Linagliptin therapy also resulted in improvements in beta-cell function.(1) Declining beta-cell function is believed to be a key factor driving the progression of type 2 diabetes.(5)

"It is imperative that blood sugar levels in people with type 2 diabetes are adequately controlled," said Dr. Giora Davidai, executive director & medical leader, medical affairs, cardiovascular & metabolic medicine, Boehringer Ingelheim Pharmaceuticals, Inc. "Uncontrolled blood sugar puts type 2 diabetes patients at a higher risk of developing serious complications like renal impairment and cardiovascular disease, which are very common in patients with type 2 diabetes."


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
2. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
3. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
4. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
11. MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... of animals. Animal vaccines are generally prepared from weakened or ... their healthy state. Some of the animal vaccines are also ... protein subunits or toxic components. These components ...
(Date:9/16/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") ... engaged primarily in the development of brachytherapy ... therapeutic applications, today announced that a patent ... brachytherapy products.  AMIC,s rights for the newly ... Battelle, under which AMIC exclusively licensed technologies ...
(Date:9/16/2014)... TUCSON, Ariz. , Sept. 16, 2014 ... describe in a case report the first ... (TAH-t) in a 13- year-old boy with failing Fontan ... When he was 3 years old, the patient ... condition known as functional single ventricle. "The Fontan operation ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 413-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... breakthrough in mental health has been developed, a cooperative ... Foundation; a preventative care program called "Safe ,til Stable." ... time of need through our live 24-hour emergency response ... the trauma experienced by individuals impacted with bipolar disorder. ...
... A Chicago woman will be among the first in the country to, ... get rid of Gastrointestinal Esophageal Reflux Disease (GERD), ... transorally, through the mouth. ... the body, the doctor uses a device to, ...
Cached Medicine Technology:Break-through Preventative Care Program for People Living With Bipolar Disorder 2New Incision-Less Procedure for REFLUX - Experts Consider it to Be Gold Standard for REFLUX 2
(Date:9/16/2014)... 2014 Marybeth Cale, owner of Cale ... of Manhattan in the small village of Rhinebeck, New York, ... business. Cale, a mompreneur, has expanded the business to incorporate ... people to maximize potential. Those services will include group trainings ... one-on-one life coaching for clients all over the country. ...
(Date:9/16/2014)... 2014 Operation Smile was founded “on the ... a facial deformity.” To spread their message and mission, the ... at the Beverly Wilshire Hotel in Beverly Hills, California. The ... whose lives have been forever transformed by the efforts of ... with Operation Smile,” said Lynda Erkiletian, Executive Director of The ...
(Date:9/16/2014)... 2014 On Friday, September 12, ... product extensions, an accompanying mobile application, the grand-opening ... tools for their sales force, and their sponsorship ... 5th annual national convention, Rise to Enterprise 2014 ... the Hyatt Regency Orange County was treated to ...
(Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... The Road , Free Education Forum for PH Patients and ... Pulmonary Hypertension Association – the country’s leading pulmonary hypertension ... pulmonary hypertension (PH) – a disease of the lungs that ... right heart failure. Without treatment, mean survivability is only 2.8 ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, ... spot human papillomavirus (HPV), which is linked to the risk ... shows that testing urine for HPV has good accuracy when ... said lead researcher Dr. Neha Pathak. She is a resident ... University of London, England. The test could be done ...
Breaking Medicine News(10 mins):Health News:Mompreneur Marybeth Cale of Cale Communications Announces Launch Of Life Coaching And Workshop Business 2Health News:James & Paula Coburn Foundation to Host the 2014 Smile Gala, Presented by Operation Smile 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 3Health News:New Products Announced at Jusuru International’s R2E14 National Convention 4Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Urine Test for HPV Works Well, Analysis Finds 2
... driving challenges this time of year, safety group says ... brings plenty of road hazards and challenges: wet leaves, lumbering ... year, September had the second-highest number of deaths per mile ... per 100 million vehicle miles, according to the National Safety ...
... ... year, 35 to 50 million Americans become infected with the flu (influenza). On average, the ... TX is taking steps to combat these preventable deaths by offering free flu shots . ... Plano, TX (Vocus) September 12, 2009 ...
... ... Pappagallo, MD, Present Partnering Primary Care Physicians with Pain Specialists , ... Las Vegas, NV (PRWEB) September 12, 2009 -- PAINWeek® ... CPE, and Dr. Marco Pappagallo, MD, teaching a Master Class that addressed the need for ...
... , , , ... leading provider of kidney care services for those diagnosed with chronic kidney ... series of 5K events raising funds and awareness of CKD across the ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) , , ...
... The Johns Hopkins Bloomberg School of Public Health has ... Research Program (OETRP) of the U.S. Department of Defense ... Bloomberg School will serve as the coordinating center for ... civilian trauma centers working together with several major military ...
... CHICAGO, Sept. 11 Schofield Media Group has promoted Brian ... U.S. and European operations consisting of five divisions and more than ... in 2006 as executive president, and in 2008 was made group ... made and continues to make a great contribution to the company," ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Need for Pain and Palliative Care Mentorship Addressed at PAINweek 2009 2Health News:DaVita Launches Nationwide Series of Kidney Awareness Run/Walks 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3
... Ruschelit® PVC. 2 eyes, oral. ... patient age. X-ray opaque line. Graduated. ... Designed to reduce kinking of the ... Ruschelit® PVC adapts to the anatomical ...
... Set® Tube with stylet inside. Sterile, ... uncuffed Rusch endotracheal tube with a ... use saving you time and storage ... for easy identification and has a ...
... Clear Plus™ Cuffed Endotracheal Tube w. Flexi -Slip™ ... Single use. A quality Rusch endotracheal tube with ... saving you time and storage space. The stylet ... withdrawal. It is designed with a soft distal ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff. Permanent connector. X-ray opaque. Single use. Sterile...
Medicine Products: